Extra Corporeal Membrane Oxygenation System Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Modality, By Application, By End-User, By Region & Competition, 2021-2031F

Description

The Global Extra Corporeal Membrane Oxygenation (ECMO) System Market is projected to expand from USD 575.2 Million in 2025 to USD 809.49 Million by 2031, exhibiting a Compound Annual Growth Rate of 5.86%. ECMO systems are advanced medical devices that offer extended cardiac and respiratory assistance by oxygenating blood outside the body for individuals suffering from severe heart or lung failure. This market growth is primarily driven by the increasing incidence of chronic cardiopulmonary conditions, a burgeoning global elderly population prone to critical organ dysfunction, and the expanding clinical deployment of these systems within adult intensive care units. For instance, the Extracorporeal Life Support Organization (ELSO) reported a total of 245,291 extracorporeal life support procedures globally through 2024, as noted in its April 2025 registry report, highlighting widespread utilization.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 575.2 Million
Market Size 2031	USD 809.49 Million
CAGR 2026-2031	5.86%
Fastest Growing Segment	Hospitals & Clinics
Largest Market	North America

Despite this growth, the market faces considerable challenges, notably the significant costs associated with acquiring ECMO devices and the complex nature of the therapy itself. Managing this sophisticated equipment and mitigating severe risks, such as bleeding or infection, necessitates a specialized multidisciplinary team, which in turn limits accessibility for smaller healthcare facilities. Therefore, the substantial financial outlay and a critical scarcity of trained professionals pose major impediments to the widespread adoption of this technology across varied healthcare infrastructures.

Market Driver

Technological progress in device portability and miniaturization is a primary catalyst for the Global ECMO System Market, facilitating quick deployment beyond conventional hospital environments. The development of compact, lightweight systems enables earlier patient intervention and safer transportation, extending life support capabilities to ambulances and smaller medical facilities. This trend is exemplified by Inspira Technologies' FDA 510(k) clearance in May 2024 for its INSPIRA ART100 system, a less invasive blood oxygenation technology. Furthermore, significant research investment, such as the over $18 million awarded to Johns Hopkins Medicine in December 2024 for creating a portable, rapid-deployment ECMO device, is further advancing these capabilities.

Simultaneously, the increasing worldwide occurrence of severe cardiopulmonary disorders is a crucial factor sustaining the demand for mechanical circulatory support. As chronic heart failure and respiratory distress become more prevalent, the need for transitional therapies to stabilize patients for recovery or transplantation intensifies. The American Heart Association's January 2024 report on heart disease and stroke statistics underscores this burden, noting over 800,000 annual cardiovascular disease deaths in the U.S., which highlights the profound clinical requirement for advanced interventions like ECMO. This expanding patient demographic motivates healthcare providers to incorporate extracorporeal support into standard critical care protocols for managing highly fatal conditions.

Market Challenge

The Global ECMO System Market's growth is considerably constrained by substantial financial costs and a severe scarcity of skilled professionals. Extracorporeal life support therapy is complex, requiring not only costly equipment but also a specialized, multidisciplinary team of experts available 24/7. This requirement establishes a significant hurdle for smaller healthcare facilities and developing regions, largely restricting market penetration to major, well-resourced academic medical centers.

As a result, the inability to implement these systems universally limits both the potential installed base and the volume of procedures performed. The intricate nature of ECMO therapy mandates diligent management to minimize risks, thereby increasing the demand for highly skilled professionals who are already in short supply. The Extracorporeal Life Support Organization's April 2025 international registry report indicates an overall survival rate of 64% to discharge or transfer for these high-acuity patients, underscoring the high level of proficiency needed. This highlights how the shortage of qualified personnel directly impedes the broader adoption of ECMO technology.

Market Trends

The swift integration of Extracorporeal Cardiopulmonary Resuscitation (ECPR) is transforming emergency medical practices by offering immediate circulatory support for refractory cardiac arrest. This method extends the critical intervention period when standard resuscitation proves ineffective, leading to its growing implementation in advanced medical facilities. As healthcare institutions standardize their cannulation techniques, the clinical success rates for this demanding procedure are showing a notable improvement. For example, an article in the Annals of Emergency Medicine (January 2025) reported that favorable neurological outcomes for ECPR patients rose to 37% by the end of the study, confirming this positive trend.

Concurrently, there is a clear trend towards adopting awake and ambulatory ECMO protocols, which are enhancing care for patients awaiting organ transplants. This innovative approach minimizes the need for sedation and mechanical ventilation, allowing patients to retain physical mobility and prevent muscle wasting before surgery. By prioritizing rehabilitation during extracorporeal support, medical professionals are significantly improving patient stability and viability for post-transplant success. The effectiveness of this strategy is highlighted in the ASAIO Journal (July 2024), where the 90-day waitlist survival rate for ambulatory veno-venous ECMO patients reached 86%, considerably surpassing that of non-ambulatory groups.

Key Market Players

Alung Technologies Inc.
Eurosets
Getinge AB
Medtronic PLC
Microport Scientific Corporation
Nipro Medical Corporation
Terumo Medical Corporation
Abbott Laboratories
Fresenius Medical Care Company

Report Scope

In this report, the Global Extra Corporeal Membrane Oxygenation (ECMO) System Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Extra Corporeal Membrane Oxygenation (ECMO) System Market, By Modality

Veno-Arterial (VA)
Veno-Venous (VV)
Others

Extra Corporeal Membrane Oxygenation (ECMO) System Market, By Application

Respiratory Applications
Cardiac Applications
Extracorporeal Cardiopulmonary Resuscitation (ECPR)

Extra Corporeal Membrane Oxygenation (ECMO) System Market, By End-User

Hospitals & Clinics
Ambulatory Care Centers
Others

Extra Corporeal Membrane Oxygenation (ECMO) System Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Extra Corporeal Membrane Oxygenation (ECMO) System Market.

Available Customizations:

Global Extra Corporeal Membrane Oxygenation (ECMO) System Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Modality (Veno-Arterial (VA), Veno-Venous (VV), Others)
- 5.2.2. By Application (Respiratory Applications, Cardiac Applications, Extracorporeal Cardiopulmonary Resuscitation (ECPR))
- 5.2.3. By End-User (Hospitals & Clinics, Ambulatory Care Centers, Others)
- 5.2.4. By Region
- 5.2.5. By Company (2025)
5.3. Market Map

6. North America Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Modality
- 6.2.2. By Application
- 6.2.3. By End-User
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Modality
    - 6.3.1.2.2. By Application
    - 6.3.1.2.3. By End-User
- 6.3.2. Canada Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Modality
    - 6.3.2.2.2. By Application
    - 6.3.2.2.3. By End-User
- 6.3.3. Mexico Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Modality
    - 6.3.3.2.2. By Application
    - 6.3.3.2.3. By End-User

7. Europe Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Modality
- 7.2.2. By Application
- 7.2.3. By End-User
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Modality
    - 7.3.1.2.2. By Application
    - 7.3.1.2.3. By End-User
- 7.3.2. France Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Modality
    - 7.3.2.2.2. By Application
    - 7.3.2.2.3. By End-User
- 7.3.3. United Kingdom Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Modality
    - 7.3.3.2.2. By Application
    - 7.3.3.2.3. By End-User
- 7.3.4. Italy Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Modality
    - 7.3.4.2.2. By Application
    - 7.3.4.2.3. By End-User
- 7.3.5. Spain Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Modality
    - 7.3.5.2.2. By Application
    - 7.3.5.2.3. By End-User

8. Asia Pacific Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Modality
- 8.2.2. By Application
- 8.2.3. By End-User
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Modality
    - 8.3.1.2.2. By Application
    - 8.3.1.2.3. By End-User
- 8.3.2. India Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Modality
    - 8.3.2.2.2. By Application
    - 8.3.2.2.3. By End-User
- 8.3.3. Japan Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Modality
    - 8.3.3.2.2. By Application
    - 8.3.3.2.3. By End-User
- 8.3.4. South Korea Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Modality
    - 8.3.4.2.2. By Application
    - 8.3.4.2.3. By End-User
- 8.3.5. Australia Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Modality
    - 8.3.5.2.2. By Application
    - 8.3.5.2.3. By End-User

9. Middle East & Africa Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Modality
- 9.2.2. By Application
- 9.2.3. By End-User
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Modality
    - 9.3.1.2.2. By Application
    - 9.3.1.2.3. By End-User
- 9.3.2. UAE Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Modality
    - 9.3.2.2.2. By Application
    - 9.3.2.2.3. By End-User
- 9.3.3. South Africa Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Modality
    - 9.3.3.2.2. By Application
    - 9.3.3.2.3. By End-User

10. South America Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Modality
- 10.2.2. By Application
- 10.2.3. By End-User
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Modality
    - 10.3.1.2.2. By Application
    - 10.3.1.2.3. By End-User
- 10.3.2. Colombia Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Modality
    - 10.3.2.2.2. By Application
    - 10.3.2.2.3. By End-User
- 10.3.3. Argentina Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Modality
    - 10.3.3.2.2. By Application
    - 10.3.3.2.3. By End-User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Extra Corporeal Membrane Oxygenation (ECMO) System Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Alung Technologies Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Eurosets
15.3. Getinge AB
15.4. Medtronic PLC
15.5. Microport Scientific Corporation
15.6. Nipro Medical Corporation
15.7. Terumo Medical Corporation
15.8. Abbott Laboratories
15.9. Fresenius Medical Care Company